The combination of our explainable AI and our extensive databases allows you to learn about treatment options. You will be provided with information on whether there is an existing treatment option that is customized for your particular type of tumor. This knowledge will be made available regardless of whether the treatment is a marketed drug or a new drug at the clinical trial stage.
OmiCure™ itself does not handle biopsy samples, nor generates next-generation sequencing (NGS) data. We engage 3rd party services, such as, core genomic facilities to generate such data.
Once we have the data from the sequencing lab, we analyze it against near 50 thousand different drug-gene interactions to find the most advanced cancer treatment which matches your tumor.
Often, it is also valuable to identify which treatments may have lower efficacy for your cancer type, so as to avoid unnecessary suffering and costs. These results will help you better understand potential therapies and may be used by your oncologist to plan your personalized precision treatment.
Although the availability of specific therapies cannot be guaranteed and is dependent on its regulatory status in your country of residence, our platform does provides you with an up-to-date knowledge of what may be available in the US and EU.
OmiCure™ cannot assess whether a drug is appropriate or gauge a patient’s ability to respond to any specific medication. Patients should not look to the report for medical advice or to make treatment decisions on their own; instead, they should only use the information to guide discussions with their health care provider.